Chemoimmunotherapy represents a tried a tested approach to Waldenström’s macroglobulinemia (WM). Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, talks on the current state of the art for WM management, commenting on the increasing number of agents physicians have at their disposal and the subsequent positive impact this has on patient outcomes. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.